TY - JOUR
TI - Investigational Drug Treatments for Triple-Negative Breast Cancer
AU - Damaskos, Christos
AU - Garmpis, Nikolaos
AU - Garmpi, Anna and
AU - Nikolettos, Konstantinos
AU - Sarantis, Panagiotis
AU - Georgakopoulou,
AU - Vasiliki E.
AU - Nonni, Afroditi
AU - Schizas, Dimitrios
AU - Antoniou,
AU - Efstathios A.
AU - Karamouzis, V, Michalis
AU - Nikolettos, Nikos and
AU - Kontzoglou, Konstantinos
AU - Patsouras, Alexandros
AU - Voutyritsa,
AU - Errika
AU - Syllaios, Athanasios
AU - Koustas, Evangelos
AU - Trakas,
AU - Nikolaos
AU - Dimitroulis, Dimitrios
JO - International Journal of Person-Centered Medicine
PY - 2021
VL - 11
TODO - 7
SP - null
PB - MDPI
SN - 2043-7730, 2043-7749
TODO - 10.3390/jpm11070652
TODO - novel therapeutic strategies; immunotherapy; targeted therapies;
PI3kb/mTOR inhibitors; PARP inhibitors; histone deacetylase inhibitors
TODO - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast
cancer (BC) and accounts for 10-20% of cases. Due to the lack of
expression of several receptors, hormone therapy is largely ineffective
for treatment purposes. Nevertheless, TNBC often responds very well to
chemotherapy, which constitutes the most often recommended treatment.
New beneficial targeted therapies are important to be investigated in
order to achieve enhanced outcomes in patients with TNBC. This review
will focus on recent therapeutic innovations for TNBC, focusing on
various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway
inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase
inhibitors, histone deacetylase inhibitors (HDACIs), and immune
checkpoint inhibitors.
ER -